Your browser doesn't support javascript.
loading
Association between specific human leukocyte antigen alleles and development of thyroid immune-related adverse event.
Sasaki, Eisaku; Natori, Yutaka; Tokuda, Emi; Kimura-Tsuchiya, Reiko; Suga, Junko; Kanazawa, Kenya; Koguchi, Tomoyuki; Kikuchi, Nobuyuki; Okabe, Naoyuki; Murono, Shigeyuki; Tachibana, Kazunoshin; Soeda, Shu; Shimabukuro, Michio; Saji, Shigehira.
Afiliação
  • Sasaki E; Department of Medical Oncology, Fukushima Medical University, Fukushima, 960-1295, Japan.
  • Natori Y; Department of Medical Oncology, Fukushima Medical University, Fukushima, 960-1295, Japan.
  • Tokuda E; Department of Medical Oncology, Fukushima Medical University, Fukushima, 960-1295, Japan.
  • Kimura-Tsuchiya R; Department of Medical Oncology, Fukushima Medical University, Fukushima, 960-1295, Japan.
  • Suga J; Division of Cancer Genome Medicine, Cancer Center, Kyoto University Hospital, Kyoto, 606-8507, Japan.
  • Kanazawa K; Department of Pulmonary Medicine, Fukushima Medical University, Fukushima, 960-1295, Japan.
  • Koguchi T; Department of Urology, Fukushima Medical University, Fukushima, 960-1295, Japan.
  • Kikuchi N; Department of Dermatology, Fukushima Medical University, Fukushima, 960-1295, Japan.
  • Okabe N; Department of Chest Surgery, Fukushima Medical University, Fukushima, 960-1295, Japan.
  • Murono S; Department of Otorhinolaryngology, Fukushima Medical University, Fukushima, 960-1295, Japan.
  • Tachibana K; Department of Breast Surgery, Fukushima Medical University, Fukushima, 960-1295, Japan.
  • Soeda S; Department of Obstetrics & Gynecology, Fukushima Medical University, Fukushima, 960-1295, Japan.
  • Shimabukuro M; Department of Diabetes, Endocrinology & Metabolism, Fukushima Medical University, Fukushima, 960-1295, Japan.
  • Saji S; Department of Medical Oncology, Fukushima Medical University, Fukushima, 960-1295, Japan.
Immunotherapy ; : 1-10, 2024 Jun 18.
Article em En | MEDLINE | ID: mdl-38889451
Everyone has a unique combination of human leukocyte antigens (HLAs) in their body that help the immune system identify threats. HLAs were named from the fact that they were first identified on the surface of human leukocytes. Afterward, HLAs were also found on all human cells. HLAs present antigens to immune cells. These HLAs also influence how the immune system attacks cancer cells. Immune checkpoint inhibitors are drugs that can help the immune system fight cancer, but they sometimes cause severe adverse events. In this study, we investigated whether specific HLA genes are related to the development of an adverse event that affects the thyroid in cancer patients treated with immune checkpoint inhibitors. We found an association between three HLA genes (A*26:01, DPA1*01:03 and DPB1*02:01) and the development of the thyroid adverse event. However, larger studies are needed to confirm and generalize these initial exploratory findings.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Immunotherapy Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Immunotherapy Ano de publicação: 2024 Tipo de documento: Article